key: cord-0965308-71is56do authors: Manuel, Oriol title: Covid-19 vaccination in solid-organ transplant recipients: generating new data as fast as possible, but taking clinical decisions as slow as necessary date: 2021-06-19 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2021.06.018 sha: 38ab3c7f478ba35795b9704ecb7ebd98f4e17912 doc_id: 965308 cord_uid: 71is56do nan After almost 18 months of the discovery of SARS-CoV-2 and the subsequent declaration by the WHO of the Covid-19 pandemic, the world continues to struggle with an unceasing number of infections and overloaded health systems. A reason for optimism is the advent of highly efficacious vaccines against SARS-CoV-2, developed within a record period using different technologies (1) (2) (3) . Among them, mRNA-based vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) seem to be the most efficacious in preventing symptomatic infection, need for hospitalization, and death (1, 2) . mRNA-based vaccines have been initially used in patients at high-risk for Covid-19-associated complications, namely the elderly, patients with chronic conditions, and immunocompromised patients. Solid-organ transplant (SOT) recipients seem to be associated with impaired outcomes of Covid-19, probably due to the disproportionate number of comorbidities present in these patients as compared to the general population (4). However, SOT recipients have not been included in phase II and III clinical trials evaluating the efficacy of SARS-CoV-2 vaccines, and they have been underrepresented in studies assessing the effectiveness of these vaccines in real life (5) . Given the absence of data coming from randomized trials on the tolerability, immunogenicity, and efficacy of SARS-COV-2 vaccines in SOT recipients, data produced by observational cohorts are highly antimetabolites, no mechanistic target of rapamycin (mTOR) inhibitors, and low calcineurin-inhibitor levels had higher chances of reaching a detectable antibody response. On the contrary, older age and impaired kidney function were expectedly associated with a lower immune response. Four seronegative patients developed symptomatic SARS-CoV-2 infection, with three severe cases including one patient who died (6) . These results of impaired immunogenicity are similar than those seen in other recent cohorts of transplant recipients, including liver (47% seropositivity rate (7)), J o u r n a l P r e -p r o o f heart (49% (8)) and lung transplant recipients (18% (9)). Patients receiving belatacept, a drug blocking the co-stimulation pathway and impairing B-cell and T-cell crosstalk, have shown the poorest responses with only 5.7% seropositivity rate in a cohort in France (10) . Overall, these results are in sharp contrast with the almost universal 100% response seen in phase I and II trials with mRNA-based vaccines in the general population. What are the clinical implications that we can extract from these studies? The first message to convey is that these results are preliminary and that more research is needed to better establish the clinical relevance of this observation. Very few studies so far have evaluated cell-mediated in addition to humoral responses to the vaccine. Preliminary data suggest that patients that did not elicit antibodies against mRNA-based vaccines may however develop some protection by cellmediated immunity (11) . More importantly, data on the clinical efficacy of these vaccines in immunocompromised patients are still missing given the lack of data on the correlation between antibody levels and clinical protection. It is essential to know whether patients with undetectable responses may still be protected against severe manifestations of Covid-19, hospitalization, and death. Previous studies suggest that despite lower antibody and cell-mediated immunity elicited by SOT recipients against influenza vaccine (12) , vaccination has been robustly associated with lower rates of severe infection and influenza-associated complications (13) . Although some cases of severe breakthrough infections have already been reported in SOT recipients, also by Rozen-Zvi et al. (6, 14, 15) , this can be expected even in immunocompetent individuals, as no vaccine is 100% efficacious against clinical disease (5) . In that regard, recent data in the general population suggest that If this lower immunogenicity of the vaccine is confirmed, how can we improve the effectiveness of the vaccine in transplant recipients? Data from interventional research already performed in SOT recipients on influenza vaccine may help to delineate novel strategies for Covid-19 vaccination, namely the use of booster or higher doses (17, 18) . In one of the largest cohorts evaluating both BNT162b2 and mRNA-1273, a significant increase in antibody levels was observed after the second dose of the vaccine (from 18% to 56%) (19) , so that the administration of a third dose of the vaccine seems to be the logical way of further boosting the immune response. Administration of a double dose (i.e. two simultaneous injections instead of one) may also potentially increase the immune response to the vaccine, although phase I and II trials with the mRNA-based SARS-CoV-2 vaccines did not show major differences in neutralization responses irrespective of the dose used (20) . Therefore, the safety and efficacy of these novel strategies should imperatively be tested in controlled trials. Another way of potentially reduce the negative effect of immunosuppression on vaccine response would be by modulating the immunosuppressive drugs levels, in particular by reducing the dose of mycophenolate immediately before and after vaccination. Again, given the potential risk for developing acute rejection with this strategy, this needs to be tested in the context of a clinical trial. The example of the research platform implemented by the John Hopkins University allowing the inclusion of patients all over the US through a digital campaign (19) , or the large number of published studies involving cohorts of vaccinated patients from Israel (6) (7) (8) (9) , shows that well-designed and adequately powered clinical trials can be rapidly implemented to answer these and other research questions. While waiting for more data, what should we say to transplant physicians and patients? Given the potential lower efficacy of the vaccine, we should transmit a message of caution by continuing to follow the basic recommendations for protection, such as mask use, hand hygiene, and social J o u r n a l P r e -p r o o f distancing. Routine use of serology for checking the response to the vaccine is not recommended at the present stage, given the lack of approved cutoffs for protection and differences in the performance of the available serological assays. A negative result of the serology can create undesirable anxiety to the patient; or on the opposite, given the wide range of antibody titers observed in SOT recipients, the result of a positive serology may lead to a false sense of protection, in particular for these patients with low titers. Cocooning vaccination of household members should be strongly encouraged, as well as rapid testing in case of symptoms compatible with Covid-19, even in vaccinated patients. But above all, we urgently need data from well-designed interventional research to fill the unknown gaps in order to apply evidence-based measures to better protect our transplant population (21). Conflict of interest disclosure : OM have received grant support from Lophius Bioscience and Advisory Board fees from MSD and Gilead. Funding : no external funding received J o u r n a l P r e -p r o o f Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Impact of COVID-19 in solid organ transplant recipients Vaccine in a Nationwide Mass Vaccination Setting Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients -Prospective cohort study Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients Immunogenicity of the BNT162b2 mRNA Vaccine in Heart Transplanted Patients-A Prospective Cohort Study Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination Occurrence of severe COVID-19 in vaccinated transplant patients Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients An mRNA Vaccine against SARS-CoV-2 -Preliminary Report